OpGen, Inc. Stock price

Equities

OPGN

US68373L4068

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT Pre-market 07:35:52 am
0.7175 USD -4.33% Intraday chart for OpGen, Inc. 0.661 -7.87%
Sales 2021 4.31M Sales 2022 2.61M Capitalization 7.57M
Net income 2021 -34M Net income 2022 -37M EV / Sales 2021 6.51 x
Net cash position 2021 10.9M Net Debt 2022 7.38M EV / Sales 2022 5.74 x
P/E ratio 2021
-0.87 x
P/E ratio 2022
-0.18 x
Employees 93
Yield 2021 *
-
Yield 2022
-
Free-Float 99.58%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.33%
1 week+37.95%
Current month+50.23%
1 month+48.86%
3 months+62.29%
6 months+246.62%
Current year+70.83%
More quotes
1 week
0.46
Extreme 0.461
0.99
1 month
0.45
Extreme 0.451
0.99
Current year
0.24
Extreme 0.24
0.99
1 year
0.17
Extreme 0.165
3.84
3 years
0.17
Extreme 0.165
74.40
5 years
0.17
Extreme 0.165
304.00
10 years
0.17
Extreme 0.165
54 400.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 60 21-12-31
Chief Operating Officer 55 20-03-31
Corporate Officer/Principal 53 20-03-31
Members of the board TitleAgeSince
Corporate Officer/Principal 53 20-03-31
More insiders
Date Price Change Volume
24-03-27 0.7175 -4.33% 3,251,277
24-03-26 0.75 +57.89% 77,674,204
24-03-25 0.475 -4.81% 6,272,524
24-03-22 0.499 -2.54% 164,213
24-03-21 0.512 -1.56% 163,641

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company's product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company's subsidiaries include Curetis GmbH and Ares Genetics GmbH.
More about the company
  1. Stock
  2. Equities
  3. Stock OpGen, Inc. - Nasdaq